studies

la/mBC - HR-positive - 1st line (L1), TKI anti HER1/EGFR and HER2/neu vs. HER2 inhibitor, meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 352,354 - treatments: 422,1304,421,1312,1326,1368,1373,1309,1302,1308